Investigational drug · Phase 3
HLX22
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
10
Any phase or sponsor naming "HLX22"
First trial start
2024
Nov 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX22", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2 + Breast Cancer
- HER2-low Hormone Receptor Positive Breast Cancer
- Gastroesophageal-junction Cancer
- Monoclonal Antibody
- Gastric Cancer
- HER2-positive Gastric Cancer
Approved drugs for the same conditions: Breast cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX22" as an intervention, largest first.
- A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07294534 · 817 participants (planned) · Start Jan 27, 2026 · Primary completion Sep 30, 2028
Drug: HLX87+HX22; HLX87 + Pertuzumab and 1 more · For: HER2 + Breast Cancer
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT07294508 · 706 participants (planned) · Start Feb 27, 2026 · Primary completion Jan 15, 2028
Drug: HLX87 + HLX22; HLX87 + Pertuzumab and 2 more · For: HER2 + Breast Cancer
Sites: Beijing, China
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerPivotal-lookingRecruiting
Shanghai Henlius BiotechIndustry
NCT06532006 · 550 participants (planned) · Start Nov 22, 2024 · Primary completion Jun 1, 2027
Drug: HLX22; Pembrolizumab and 3 more · For: Gastroesophageal-junction Cancer; Monoclonal Antibody; Gastric Cancer and 1 more
Sites: Anaheim, California; Los Alamitos, California; Greeley, Colorado · 208 sites in all
- Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerPivotal-lookingStatus unknown
Shanghai Henlius BiotechIndustry
NCT04908813 · 150 participants (planned) · Start Sep 29, 2021 · Primary completion Dec 2024
Drug: HLX22; Placebo and 3 more · For: Gastric Cancer
Sites: Shanghai, China
- HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal CancersNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07938021 · 128 participants (planned) · Start Dec 1, 2026 · Primary completion Mar 1, 2028
Drug: HLX22; Serplulimab and 2 more · For: Gastric Cancer (Diagnosis); Colorectal Cancer (Diagnosis); Gastroesophageal Junction Cancer and 1 more
Sites: Wuhan, China
- A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07824869 · 90 participants (planned) · Start Oct 31, 2026 · Primary completion Mar 31, 2028
Drug: HLX22; Trastuzumab and 5 more · For: HER2 + Breast Cancer
Shanghai Henlius BiotechIndustry
NCT06832202 · 50 participants (planned) · Start Apr 16, 2025 · Primary completion Jun 1, 2027
Drug: HLX22; Trastuzumab Deruxtecan · For: HER2-low Hormone Receptor Positive Breast Cancer
Sites: Shanghai, China
- A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and ChemotherapyActive, not recruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07176702 · 45 participants (planned) · Start Sep 30, 2025 · Primary completion Mar 5, 2027
Drug: HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy · For: Metastatic PDAC; HER2-positive Status
Sites: Nanjing, China; Shanghai, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07943533 · 30 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: HLX22; Trastuzumab and 2 more · For: HER2-Positive; Limited Metastatic; Gastric Cancer
Shanghai Henlius BiotechIndustry
NCT03916094 · 11 participants · Start Jul 31, 2019 · Primary completion Jan 4, 2021
Drug: HLX22 · For: Solid Tumor
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Different Treatment Regimens for Previously Untreated Patients with HER2-positive Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials.
He Y, Kang Q, Xu S, et al. · J Gastrointest Cancer 2025
- Dual HER2 inhibition: Is two better than one?
Strickland MR, Klempner SJ · Med 2024
- A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.
Li N, Qiu M, Zhang Y, et al. · Med 2024
- Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
Wei R, Zhang W, Yang F, et al. · J Transl Med 2024
- HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial.
Zhu X, Ding Y, Wang Q, et al. · Invest New Drugs 2023
Also in development for HER2 + Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.